Microglia are widely accepted as surveillants in the central nervous system that are continually searching the local environment for signs of injury. Following an inflammatory situation, microglia alter their morphology, extend ramified processes, and undergo cell body hypertrophy. Extracellular nucleotides are recognized as a danger signal by microglia. ADP acting on P2Y12 receptors induce process extension of microglia thereby attracting microglia to the site of adenosine tri-phosphate/ADP leaking or release. However, the question whether ADP/P2Y12 receptor signaling directly stimulates the production or release of inducible factors such as cytokines remains unclear. In this study, we found that CC chemokine ligand 3 (CCL3) is induced by ADP-treated primary microglia. Pharmacological characterization using pertussis toxin, a P2Y12 receptor inhibitor, and a calcium chelator revealed that CCL3 induction was caused by P2Y12 receptor-mediated intracellular calcium elevation. Next, nuclear factor of activated T-cell dephosphorylation and nuclear translocalization were observed. Calcineurin, an inhibitor for nuclear factor of activated T cell, suppressed CCL3 induction. These data indicate that microglial P2Y12 receptors are utilized to trigger an acute inflammatory response in microglia via rapid CCL3 induction after ADP stimulation.
Microglia are the resident immune cells in the central nervous system and have many important roles in several neurologic disorders including Alzheimer's disease, multiple sclerosis, Parkinson's disease, and neuropathic pain (Hanisch and Kettenmann 2007; Ransohoff and Perry 2009; Tsuda et al. 2011) . Microglia are activated by various factors, such as viruses, b-amyloid, oligo DNA/RNA, chemokines, cytokines, and complement. Extracellular nucleotides are also known to be potent stimulators of microglia (Inoue 2006) and have an important role in the inflammatory and immune response of microglia (Di Virgilio et al. 2009 ). Accumulating evidence reveals that purinergic signaling acts as gliotransmitter or neurotransmitter and can affect many neurological diseases via purine and pyrimidine receptors (Burnstock 2008; Burnstock et al. 2011) . Microglia express several purinergic receptors that are involved in the microglial motility of ramified processes, migration, cytokine release, and phagocytosis/macropinocytosis (Bianco et al. 2006; Haynes et al. 2006; Koizumi et al. 2007; Ohsawa et al. 2007; Uesugi et al. 2012) . Pathologically, the microglial purinergic receptors subtypes ionotropic P2X4 receptor and the G-protein-coupled P2Y12 receptor (P2Y12R) play an important role in neuropathic pain in spinal cord microglia (Tsuda et al. 2003; Tozaki-Saitoh et al. 2008) . P2Y12R is one of the metabotropic Gi-protein-coupled transmembrane receptors and has a crucial role in microglial motility such as chemotaxis and membrane raffling (Honda et al. 2001; Haynes et al. 2006; Ohsawa et al. 2007 ). In addition, in vivo and ex vivo studies show that P2Y12R is necessary for the extension and migration of microglial processes and the cell body, respectively, during injury (Davalos et al. 2005; Haynes et al. 2006; Kurpius et al. 2007) . Interestingly, in the central nervous system, P2Y12Rs are expressed selectively in microglia (Sasaki et al. 2003; Butovsky et al. 2014) and thus, seem to have a significant role in neurological disorders. However, few reports demonstrate the contribution of P2Y12R in CNS disorders. Although P2Y12R has been associated with neuropathic pain, the mechanisms underlying this link remain unclear.
Chemokines are a family of cytokines secreted by immune cells that have chemotactic function and induce pro-inflammatory responses. Chemokine release is one of the important microglial functions in several pathological conditions (Kataoka et al. 2009; Shiratori et al. 2010) . In the pathology of neuropathic pain, accumulating evidence indicates that some chemokines play important roles (White et al. 2007; Gao and Ji 2010; Biber et al. 2011; Kiguchi et al. 2011) . We, and other groups, have recently reported that C-C chemokine ligand 3 (CCL3) chemokine expression was increased in the peripheral injured site and also in the spinal cord in neuropathic pain conditions (Kiguchi et al. 2010; Matsushita et al. 2014) and that the CCL3 receptor CCR5 is crucial for the development of neuropathic pain (Padi et al. 2012) . In addition, CCR5 antagonists have been shown to be effective in the treatment of neuropathic pain (Matsushita et al. 2014) . Therefore, in this study, we were motivated to assess our hypothesis that P2Y12R activates the signaling inducing CCL3 expression in primary microglia.
Materials and methods

Cell culture
Rat primary cultures of microglia were obtained from mixed glial cultures prepared from fore brain of neonatal Wistar rats and maintained for 10-21 days in Dulbecco's modified Eagles medium (Invitrogen, Carlsbad, CA, USA) with 10% (v/v) fetal bovine serum, penicillin, and streptomycin (20 U/mL). Microglia were isolated as floating cells by gentle shaking for 3 min and allowed to attach to appropriate dishes. Purity of microglia (above 95%) was confirmed by immunocytochemical staining with anti-iba1 antibody. Two hours after isolation, culture medium was replaced with conditioned medium (fresh culture medium mixed with mixed primary glial culture-conditioned medium at 3 : 1) and incubated overnight. No apparent cell death of microglia was observed in these conditions. Animal treatment and experiments were conducted in accordance with the guidelines of Kyushu University.
Reagents ATP, ADP, UTP, UDP, MRS2179, actinomycin D, cycloheximide, dibutyryl-cAMP, KT5720, Xestospongin, ionomycin and (3 0 )-O-(4-Benzoylbenzoyl)adenosine 5 0 -triphosphate (BzATP) were purchased from Sigma chemical company (St Louis, MO, USA). ARC66096 and 2-methylthio-ADP were purchased from TOCRIS (Bristol, UK). Cyclosporin A was purchased from Biomol International LP (Plymouth Meeting, PA, USA). BAPTA, BAPTA-AM and INCA-6 were purchased from Calbiochem (San Diego, CA, USA), pertussis toxin was purchased from Wako (Tokyo, Japan).
RNA extraction and Real-time RT-PCR Total RNA was obtained using the Cell Amp Direct RNA prep kit for RT-PCR (Takara, Kyoto, Japan) according to the manufacture's protocols. Cells were cultured in 96 well plates at 1 9 10 4 /well.
Three to five wells were prepared for each treatment from the same batch of mixed glial cell culture, and two to four different batches were used for experimental replication. Total RNA was subjected to real time RT-PCR using the Takara One
Step Prime Script RT-PCR kit (Takara) according to the manufacturer's protocol. Data were obtained using an ABI Prism 7500 sequence detection system (Applied Biosystems, Foster City, CA, USA) and analyzed using 7500 System SDS Software 1.3.1 (Applied Biosystems). CCL3 mRNA expression levels in each sample were normalized to the levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA, and normalized with the mean value of control treatments in same set of experiments, and mean value from all data were depicted. The sequences of primers and the TaqMan fluorogenic probe are listed in Table 1 .
Measurement of CCL3 release
Rat primary microglia were isolated as described above and were plated in 24-well plates (3 9 10 5 cells/well). After ADP stimulation for 1 h, the supernatants were collected and centrifuged (4°C, 1000 g, 10 min). Supernatants were used to measure chemokine release. The concentration of CCL3 in each sample was determined using mouse the CCL3/MIP-1a ELISA kit (R&D systems, Oxon, UK). The assay was performed according to the manufacturer's protocol. ] and then incubated with horseradish peroxidase-conjugated secondary antibody (1 : 1000; GE Healthcare Japan (Tokyo, Japan)). The blots were visualized using a chemiluminescence method (Chemi-Lumi system) and a LAS-3000 imaging system (Fujifilm, Tokyo, Japan).
Immunocytochemical analysis
Microglia cells were seeded onto aminopropyltriethoxysilane-coated glass chamber slides (Matsunami) at 3 9 10 4 cells/well and incubated for 60 min. After medium replacement, medium only or ADP or ionomycin was added, and fixed at indicated time by replacing the medium with ice cold 3.7% paraformaldehyde diluted in phosphatebuffered saline (PBS). After fixation for 10 min at 22-25°C, the cells were washed with PBS, permeabilized and blocked with 3% normal goat serum diluted in 0.1% Triton X-100/PBS for 15 min at 22-25°C. The anti-NFAT1 antibody (1 : 100, D43B1; Cell Signlaing Technology Japan, K.K., Totyo, Japan) was incubated overnight at 4°C. After washing the primary antibody, a secondary antibody [Alexa Fluor 488 goat anti-rabbit antibody (1 : 1000)] and Texas-Red phalloidin (1 : 100) were incubated for 60 min at 22-25°C with protection from the light. Finally, the cells were mounted in an antifade product containing 4 0 ,6-Diamidino-2-phenylindole, dihydrochloride (Vector Laboratories, Burlingame, CA, USA) and coverslips were applied. Images were obtained by a confocal microscope (LSM5 Pascal with Plan-Apochromat 20x/0.8 lens; Carl Zeiss). Analysis of nuclear NFAT immunofluorescence was performed using Image J software (https://imagej.nih.gov/ij/, Version 1.50d), regions of interest were made from the shape of DAPI staining and mean fluorescent intensity in the region was measured for each cell nucleus.
Statistical analysis
All data are represented as means AE SEM. Statistical analyses of the results were evaluated using SigmaPlot (Version 11.0; Systat Software, Inc., Evanston, IL, USA) the unpaired Student's t-test, one-way analysis of variance (ANOVA) with Bonferroni t-test for multiple comparison. Differences having a probability p < 0.05 were considered statistically significant.
Results
ADP increases CCL3 mRNA expression and protein release in rat primary microglia We first examined the effect of ADP, a P2Y12R agonist, on CCL3 gene expression in rat primary microglia. We found a significant increase in the level of CCL3 mRNA at 30 min after stimulation (Fig. 1a) . This effect was concentration-and time-dependent ( Fig. 1a and b) . The significant CCL3 mRNA expression was induced by at least 10 lM ADP from 15 min to 30 min after ADP stimulation. To address whether this ADP-induced CCL3 mRNA increase occurred by de novo synthesis, we pre-treated cells with actinomycin D, a RNA polymerase inhibitor, and found that actinomycin D completely suppressed ADP-induced CCL3 mRNA expression ( Fig. 1c) . Using ARC69931MX, a P2Y12R antagonist, and MRS2179, a selective antagonist at P2Y1R, we determined the subtypes of P2 receptors involved in ADP-induced CCL3 expression. Pre-treatment with ARC69931MX significantly suppressed ADP-induced CCL3 mRNA expression, but MRS2179 did not have any suppressive effect ( Fig. 1d ). In addition, 2-methyl-thio ADP, an agonist to P2Y12R, also increased CCL3 mRNA expression. Another P2Y12R antagonist ARC66096 also completely inhibited ADP-induced CCL3 mRNA expression (Fig. 1e) . To investigate whether ADP could elevate not only gene expression but also protein release, we measured the amount of CCL3 protein in the supernatants of rat primary microglia after 1 h ADP stimulation by ELISA and found that CCL3 protein release was up-regulated by ADP stimulation (Fig. 1f) .
G i signaling and increase in intracellular Ca 2+ is essential for ADP-induced gene expression Since P2Y12R is a G i -protein-coupled receptor, thus we assessed the effect of the G i protein inactivator pertussis toxin (PTX), and found that PTX pre-treatment markedly suppressed ADP-induced CCL3 mRNA expression (Fig. 2a) (Fig. 2f) . These results suggested that elevation of [Ca 2+ ] i via both intracellular store and influx from extracellular space was involved in the mechanism of ADP-induced CCL3 expression.
Involvement of Gi-cAMP-PKA signaling in ADP-induced CCL3 induction P2Y12R is a G i class G-protein-coupled receptor that can reduce intracellular cAMP concentrations by regulating adenylate cyclase (Zhang et al. 2001; Cattaneo et al. 2003) , and cAMP concentrations can regulate protein kinase A (PKA). We thus checked the involvement of G bc by gallein (50 lM) treatment, and G bc -related signaling molecule, PI3-kinase using wortmannin (100 nM) and LY294002 (40 lM). Any of the three inhibitors did not have effect on ADP-induced CCL3 mRNA expression ( Fig. 3a and b) . We checked the involvement of cAMP signaling for ADPinduced CCL3 mRNA expression using dibutyryl-cAMP (dbcAMP), a cAMP potent analog, and KT5720, a PKA inhibitor. The results showed that PKA inhibition by KT5720 (5 lM) did not affect ADP-induced CCL3 elevation, however, dbcAMP (100 lM) completely suppressed CCL3 mRNA expression (Fig. 3c and d) . Unlike gene expression, dbcAMP did not affect ADP-induced [Ca 2+ ] i (Fig. 3e ). These observations imply that the G i -mediated decrease in cAMP levels necessary gating step for regulating ADP-induced CCL3 mRNA elevation via P2Y12R.
Phospholipase C and IP3R signaling is involved in ADPinduced gene expression Gi-protein-coupled receptors are known to activate Phospholipase C (PLC) (Wu et al. 1993; Kuang et al. 1996; Smit et al. 2003) , and ADP can activate PLC signaling via P2Y12R in microglia (Irino et al. 2008) . To assess this signaling pathway, we used U73122, a PLC inhibitor, and its inactive analog U73343 as a negative control. We found that U73122 pre-treatment suppressed ADP-induced CCL3 mRNA expression (Fig. 4a) ] i increases in microglia (representative traces from measurement of 20 and 60 cells). Experiments demonstrating mRNA expression levels were replicated three time and mean from total data were presented. elevation (Fig. 4b) . These results suggest that PLC signaling is involved in ADP-induced mRNA expression. In addition, an IP3R blocker, Xestospongin C, showed significant inhibition of ADP-induced CCL3 mRNA expression (Fig. 4c) . Ca 2+ imaging revealed that pre-treatment with Xestospongin C suppressed ADP-induced [Ca 2+ ] i elevations (Fig. 4d) .
NFAT is activated in ADP-stimulated primary microglia Previous studies reported that P2X7 receptor (P2X7R) and P2Y6 receptor (P2Y6R) trigger microglial release of CCL3 by which activation of NFAT is involved in a common key mechanism (Kataoka et al. 2009; Kim et al. 2011) . NFAT is one of the major ubiquitously expressed transcription factors regulating the gene expression of many cytokines and chemokines in response to intracellular calcium signaling, and has a crucial role in the development and function of the immune system (Rao et al. 1997; Macian 2005; Muller and Rao 2010) . Calcineurin, a calcium and calmodulin-dependent phosphatase, is a mediator of NFAT signaling and to induce dephosphorylation of NFAT proteins and their nuclear translocation. In 5 NFAT family members identified, a previous report showed that microglia expressed two subtypes NFAT1 and NFAT2 (Nagamoto-Combs and Combs 2010). First, we confirmed that ADP stimulation could activate NFAT signaling using western blotting. We used an NFAT1 and NFAT2 specific antibody to detect several isoforms of NFAT (open arrowhead). We detected a clear NFAT1 band shift toward a low molecular weight following ADP stimulation (closed arrowhead), which implies dephosphorylation of NFAT (Fig. 5a ). Ionomycin and BzATP were used as positive controls for NFAT activation, and induced a clear band shift, which was consistent with previous reports (Kataoka et al. 2009 ). The degree of shift was the same as samples from ADPstimulated microglia (Fig. 5a) . Furthermore, pre-treatment with ARC66096 completely blocked ADP-induced NFAT1 dephosphorylation (Fig. 5a ). NFAT2 also showed signs of dephosphorylation after ionomycin and BzATP treatment, and a faint dephosphorylated NFAT2 band was detected from ADP-stimulated microglia (Fig. 5b) .
Activation of NFAT leads to nuclear translocation of NFAT. To confirm this point, we applied immunostaining of NFAT to primary cultured microglia. Ionomycin induced a strong signal of NFAT staining in the nucleus of primary microglia. With similar localization, 30 lM ADP induced weak, but significant, nuclear staining of NFAT1 in about 10% of microglia (Fig. 5c-e) . Thus, the results suggested that P2Y12R activation leads to NFAT activation in primary microglia.
ADP-induced CCL3 expression is mediated by NFAT signaling in primary microglia Finally, we assessed whether ADP-induced CCL3 induction is inhibited by suppression of NFAT activation. We used the calcineurin inhibitor cyclosporine A and the NFAT inhibitor INCA-6. As a result, we found that pre-treatment with both cyclosporine A and INCA-6 significantly suppressed ADP- induced CCL3 mRNA expression (Fig. 6) . Together, our findings indicate that P2Y12R signaling activates NFAT1 and leads to de novo expression of CCL3.
Discussion
Most studies of microglial P2Y12R have focused on motility and chemotactic activity. Presently, there is some consensus that ATP released or leaked from damaged cells attracts neighboring microglia. Microglia extend their ramified thin processes toward the site of the ATP source to insulate the damaged region from the intact environment, or remove deleterious substances and cellular debris through phagocytosis (Kettenmann 2007; Koizumi et al. 2007) . In our study, we found that P2Y12R activation induces CCL3 chemokine production in rat primary cultured microglia. Signaling triggered by P2Y12R involved the PLC pathway, calcineurin, and NFAT1 activation. Thus, with the fast morphological responses, microglial P2Y12R may trigger inflammatory responses simultaneously.
Microglia produce several chemokines. Previous reports show that lipopolysaccharide (LPS), tumor necrosis factor a and transforming growth factor-b1 stimulation induce microglial chemokine (C-C motif) ligand 3 (CCL3) production (McManus et al. 1998) . In purinergic signaling, P2X7R and P2Y6R also mediate microglial CCL3 release (Kataoka et al. 2009; Fang et al. 2011; Kim et al. 2011) . P2X7R can be activated by relatively high concentrations of ATP. Therefore, activation of P2X7R signaling is usually assumed to occur in close vicinity of an ATP source, such as during tissue injury or cell damage, because ATP is rapidly metabolized by ectonucleotidases. In contrast, P2Y12R can be activated by much lower concentrations of ADP, which is a metabolite of ATP. Thus, in comparison with P2X7R, microglia may be able to recognize injury more readily via P2Y12R.
In this study, we found that ADP-induced CCL3 mRNA expression involved calcium signaling via Gi-mediated signaling, which was followed by PLC activation and IP3 receptor activation. Microglia elicit a calcium response to purine and pyrimidine nucleotides through activation of P2X4, P2X7, P2Y6, and P2Y12 receptors. P2X receptors are a family of ATP sensitive cation channels. The P2Y6R is coupled to G aq and induces calcium efflux from intracellular stores by UDP, and P2Y12R is activated by ADP and is coupled to G ai . Our results demonstrate that intracellular calcium signaling is an important factor for CCL3 induction because chelating intracellular and extracellular calcium ions significantly suppresses CCL3 mRNA expression. Storeoperated extracellular calcium entry may contribute to ADPinduced CCL3 induction to some degree, because calcium influx mediated by STIM and ORAI is associated with P2Y12R activation (Michaelis et al. 2015) . ADP-induced calcium signaling was significantly suppressed by pretreatment with BAPTA-AM, PTX, and PLC inhibitors, which are linked to the suppression of CCL3 mRNA expression. These results indicate that intracellular Ca 2+ influx is essential for P2Y12R-mediated CCL3 mRNA expression. Moreover, the IP3 receptor inhibitor Xestospongin C inhibited ADP-induced intracellular Ca 2+ influx and CCL3 mRNA expression. Therefore, these results imply that IP3, which is produced by activated PLC, is involved in ADP-induced Ca 2+ influx. We also tested gallein, a G bcdependent cellular activities inhibitor, but could not see any effect on CCL3 expression and [Ca 2+ ] i elevation. Thus the mechanism for G ai -mediated [Ca 2+ ] i elevation of microglial P2Y12Rs still remains to be elucidated.
P2Y12Rs have been shown to modulate adenylate cyclase and reduce cAMP via G i protein signaling in platelets (Cattaneo 2011) , and reduced cAMP might suppress PKA activation. Some reports suggest that PKA negatively modulates calcineurin-mediated NFAT activation (Sheridan et al. 2002) . In this study, we tested the effect of the cAMP analog dbcAMP and the PKA inhibitor KT5720. Pretreatment with dbcAMP completely suppressed ADPinduced CCL3 mRNA expression; however, KT5720 alone did not enhance CCL3 mRNA expression. These results imply that the reduction in cAMP by G i protein function plays a role as a gate to the induction of ADP-calcium-NFAT signal activation leading to CCL3 mRNA expression. Accumulating evidence has shown that elevation of cAMP levels may suppress the expression of humoral factors. With respect to inflammatory cytokines, cAMP analog treatment of microglia suppresses LPS-induced TNF-a, IL-6, IL-12, and CCL3 expression (Murphy et al. 1995; Petrova et al. 1999; Zhang et al. 2002; Woo et al. 2003; McIlvain et al. 2010) . A study has shown that there are two effectors under cAMP second messenger control, PKA and Epac, which play differential modulatory roles in the inflammatory response of microglia (Liu et al. 2011) . Furthermore, understanding the role of the cAMP second messenger system, especially after G ai activation, in microglia would be beneficial for finding a regulatory factor of microglial inflammatory activation.
We demonstrated that NFAT was activated by P2Y12R stimulation. In addition, we showed that P2Y12R was involved in ADP-induced CCL3 mRNA expression as a transcriptional factor. In the CNS, several reports indicate that NFAT is involved in axon extension, cell survival, apoptosis, and neuronal inflammation associated with aging (Graef et al. 2003; Benedito et al. 2005; Luoma and Zirpel 2008; Abdul et al. 2009 ). In previous reports related to microglia, it was reported that P2X7Rs stimulated by ATP or P2Y6Rs stimulated by UDP also mediate NFATc1 activation in microglia To investigate the involvement of NFAT signaling in ADPinduced CCL3 mRNA expression, we tested Cyclosporine A (CsA), a calcineurin inhibitor, and INCA-6, an NFAT inhibitor. Pre-treatment with 100 ng/mL CsA and 50 lM INCA-6 for 15 min or 10 min before ADP stimulation significantly inhibited ADP-induced CCL3 mRNA expression (n = 3 each, **p < 0.01, ***p < 0.001 vs. vehicle, ###p < 0.001 vs. ADP, Bonferroni t-test after one-way ANOVA, n = 10 wells each). (Kataoka et al. 2009; Shiratori et al. 2010; Kim et al. 2011) . Usually, continuous NFAT activation is associated with a persistent intracellular Ca 2+ increase (Shigemoto-Mogami et al. 2001; Koizumi et al. 2007) . In our study, we revealed that a P2Y12R-mediated transient Ca 2+ increase is enough to activate NFAT signaling, which leads to de novo CCL3 protein expression. We have previously reported that P2Y12Rs expressed on spinal cord microglia play a key role in neuropathic pain (Tozaki-Saitoh et al. 2008) , and CCL3 mRNA levels are up-regulated in activated microglia isolated from spinal cord tissue after peripheral nerve injury (Matsushita et al. 2014; Ochi-ishi et al. 2014) . Since the past study demonstrated that the inhibition of CCL3-CCR5 signaling suppress the development of neuropathic pain, further studies assessing P2Y12R-mediated NFAT activation and CCL3 induction in the pathophysiology of neuropathic pain may beneficial for finding new therapeutic target of microgliamediated neuropathic pain.
In this study, we have shown that P2Y12R in microglia link to NFAT activation to induce CCL3. These data suggest that microglial P2Y12 receptors are needed to trigger an acute inflammatory response in microglia via NFAT activation leading to rapid chemokine induction, such as CCL3, after ADP stimulation.
